PDC*LINE PHARMA
PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens. PDC*line Pharma originated from a flagship R&D program of the French Blood Bank (EFS, Etablissement Français du Sang) where PDC*line, a proprietary Plasmacytoid Dendritic Cell line (PDC) was developed from a patient with a PDC leukemia. Laurent LEVY President France & COO, and Joel PLUMAS, CSO founded the company in April 2014 in Grenoble and took the project to the clinical development stage with non-dilutive funding. Eric Halioua joined the team in February 2016, and became President and CEO in July 2016.
PDC*LINE PHARMA
Industry:
Biotechnology Health Care Therapeutics
Founded:
2014-04-01
Address:
La Tronche, Rhone-Alpes, France
Country:
France
Website Url:
http://www.pdc-line-pharma.com
Total Employee:
1+
Status:
Active
Contact:
+33 (0) 4 84 35 05 04
Email Addresses:
[email protected]
Total Funding:
41.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics Font Awesome Euro Google Maps
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Elstar Therapeutics
Fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating multi-functional therapeutics.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Employees Featured
Founder
Investors List
Hansongneotech
Hansongneotech investment in Series B - PDC*line Pharma
Alpha Holdings
Alpha Holdings investment in Series B - PDC*line Pharma
S.R.I.W.
S.R.I.W. investment in Series B - PDC*line Pharma
Korea Investment Partners
Korea Investment Partners investment in Series B - PDC*line Pharma
UTC Investment Co.
UTC Investment Co. investment in Series B - PDC*line Pharma
Brain Asset Management
Brain Asset Management investment in Series B - PDC*line Pharma
SFPI-FPIM
SFPI-FPIM investment in Series B - PDC*line Pharma
Sambrinvest
Sambrinvest investment in Series B - PDC*line Pharma
Meusinvest (Noshaq)
Meusinvest (Noshaq) investment in Series B - PDC*line Pharma
Shinhan-Cognitive Start-up Fund
Shinhan-Cognitive Start-up Fund investment in Series B - PDC*line Pharma
Official Site Inspections
http://www.pdc-line-pharma.com Semrush global rank: 9.33 M Semrush visits lastest month: 174
- Host name: cluster013.ovh.net
- IP address: 213.186.33.24
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "PDC*line Pharma"
About us - PDC*line Pharma
In January 2024, PDC*line Pharma and partners receive €8.1M additional grant from the Walloon region to develop PDC*neo for colorectal cancer. In April 2024, PDC*line Pharma is selected …See details»
PDC*line Pharma - Crunchbase Company Profile
PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an …See details»
Our team - PDC*line Pharma
PDC*line Pharma SA Légia Park Boulevard Patience et Beaujonc n°3 bte 6 4000 Liège Belgium +32(0) 4 242 77 56. [email protected]. Contact us. Your name. First name. Your …See details»
PDC*line Pharma SAS | European Clinical Trials Information Network
PDC*line Pharma SAS is a biotech company that specializes in developing innovative immunotherapies for the treatment of cancer. Founded in 2014, the company has quickly …See details»
PDC*line Pharma - LinkedIn
PDC*line Pharma | 4,829 followers on LinkedIn. A novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) | …See details»
PDC Line Pharma Company Profile - Office Locations, Competitors …
PDC Line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid …See details»
PDC*line Pharma - Lyonbiopôle
Apr 9, 2024 Our organization; Profile of our members; Structural projects; Public funders; Become a member; News & Events ... PDC*line Pharma . Member of Lyonbiopole . Spin-off of …See details»
PDC*Line Pharma
Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in phase I/II clinical trial (PDC*lung) and neoantigens (PDC*Neo). …See details»
PDC*line Pharma - healthtechinnovationdays6.com
Founded in 2014, PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade …See details»
PDC*line Pharma - PitchBook
Dec 6, 2016 PDC*line Pharma General Information Description. Developer of active immunotherapies designed to be used for cancer treatments. The company's …See details»
PDC*line Pharma - Funding, Financials, Valuation & Investors
Organization. PDC*line Pharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Funding Rounds 5. ... Series B - …See details»
PDC*line Pharma - VentureRadar
Feb 5, 2022 "Founded in April 2014 as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is …See details»
Investors | PDC*line Pharma
In march 2019, PDC*line Pharma granted exclusive license in South Korea and exclusive option in other Asian countriesto LG Chem Life Sciences Company, for the development and …See details»
PDC*line Pharma - Products, Competitors, Financials, Employees ...
PDC*line Pharma is a biotech company focused on the development of innovative cancer immunotherapies. Use the CB Insights Platform to explore PDC*line Pharma's full profile. …See details»
PDC*line Pharma - Crustdata Company Profile, Funding and Growth
PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid …See details»
PDC*line Pharma and partners receive €8.1M from Walloon
Jan 18, 2024 About PDC*line Pharma. Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an …See details»
PDC*line Pharma and Partners Receive €8.1M From Walloon …
Jan 17, 2024 LIÈGE, Belgium & GRENOBLE, France, January 17, 2024--PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active …See details»
Product pipeline - PDC*line Pharma
Our lead candidate, PDC*lung, is currently in the phase 1b/2 clinical trial for Non-Small Cell Lung Cancer. PDC*line Pharma plans to conduct clinical trials to reach clinical proof of concept by …See details»
All news - PDC*line Pharma
AACR 2024: PDC*line Pharma presents interim clinical results from last cohort of patients in phase I/II trial with PDC*lung01 cancer vaccine April 2024 Intermediary results of high dose …See details»